Key Takeaways KYMR started dosing in the phase IIb BREADTH study of KT-621 for eosinophilic asthma.KYMR's asthma study tests three doses of KT-621 in adults over 12 weeks, with FEV1 as the primary endpoint.KYMR is also running another phase IIb AD study of KT-621, with asthma data due in late 2027.Kymera Therapeutics (KYMR) announced that it has begun dosing patients in the phase IIb BREADTH study of KT-621 for moderate-to-severe eosinophilic asthma. KT-621 is an investigational, first-in-class, once-daily, ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BREADTH Phase 2b clinical tri ...

Core Insights - Kymera Therapeutics, Inc. (NASDAQ:KYMR) is recognized as one of the 14 best booming stocks to buy, with shares increasing over 28% in the last three months and a projected further increase of nearly 60% as of January 12 [1] Group 1: Stock Performance and Analyst Ratings - The stock has seen a 28% increase over the past three months, but Wolfe Research downgraded it to Peer Perform from Outperform on January 6 and removed its $92 price target [2] - Despite the downgrade, Wolfe Research considers Kymera a good long-term investment, although it cites a lack of catalysts for short-term upside and valuation concerns [3] - BTIG has reiterated a Buy rating with a price target of $138, while Citigroup maintained its Buy rating with a target of $110 [4] Group 2: Company Developments - In December, Kymera received Fast Track designation from the FDA for its KT-621 oral STAT6 degrader aimed at treating atopic dermatitis, following positive results from the BroADen Phase 1b clinical trial [5] - The company focuses on developing protein degradation therapies to address significant medical issues [5]

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

PresentationGood morning, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have the CEO from Kymera Therapeutics, Nello Mainolfi. I'll now pass the mic to their CEO for a short presentation, followed by a live audience Q&A.Nello MainolfiCo-Founder, President, CEO & Director Thanks, Brian. Thanks, everybody, for joining us. Hopefully, the sound is good. Always great to be at JPMor ...

Summary of Kymera Therapeutics FY Conference Call Company Overview - **Company**: Kymera Therapeutics (NasdaqGM:KYMR) - **Event**: FY Conference at the 44th J.P. Morgan Healthcare Conference - **Date**: January 13, 2026 - **CEO**: Nello Mainolfi Key Points Company Vision and Strategy - Kymera aims to develop a new generation of oral drugs with biologics-like activity, focusing on immunology [2][6] - The company has spent 10 years building its strategy, capabilities, and team to achieve this vision [2] Recent Achievements - 2025 was a pivotal year, with the completion of early clinical translation of KT-621, demonstrating effective degradation of STAT6 in humans [3][4] - Initiated a Phase 1 study for KT-621 and presented a new program, KT-579, targeting IRF5 [4][5] - Collaborations with Sanofi and Gilead, raising nearly $1 billion to fund operations through at least 2029 [5] Market Opportunity - Over 100 million patients in major markets suffer from immune-inflammatory diseases, but only about 5 million access advanced systemic therapies [9] - Kymera aims to transform treatment paradigms by offering oral drugs that provide the efficacy and safety of biologics [10] Product Pipeline - **KT-621**: Targeting IL-4 and IL-13 pathways, with Phase 2b studies initiated for atopic dermatitis (AD) and asthma [13][29] - **KT-579**: A new program targeting IRF5, with a Phase 1 study expected to start soon [14] - **IRAK4 Degrader (KT-485)**: Second-generation degrader in collaboration with Sanofi [5] Clinical Data and Efficacy - KT-621 showed robust reductions in biomarkers associated with type 2 inflammation, including TARC and Eotaxin, with effects comparable to or superior to existing biologics [22][23] - Demonstrated significant improvements in clinical endpoints for AD, including reductions in itch and sleeplessness [27][28] - The drug is designed to be effective regardless of the severity of the disease or prior treatment with biologics [26] Safety Profile - KT-621 has shown a compelling safety profile with no treatment-related adverse events reported in clinical studies [35] Future Plans - Kymera plans to complete enrollment for the AD study and continue the asthma study, with data expected by 2027 [39] - The company aims to initiate multiple Phase 3 studies in parallel for various indications [37] Market Dynamics - The current market for biologics targeting type 2 inflammation is valued at $20-30 billion, with Kymera aiming to expand this market by increasing patient access to effective oral therapies [19][20] Conclusion - Kymera Therapeutics is positioned to lead a transformation in the treatment of immune-inflammatory diseases through innovative oral therapies that combine the efficacy of biologics with the convenience of oral administration [7][10]

Kymera's Strategy and Pipeline - Kymera is focused on developing oral degrader medicines with biologics-like activity to transform immunology treatments[7, 16] - The company's pipeline includes KT-621 (STAT6 degrader), KT-579 (IRF5 degrader), and KT-485 (IRAK4 degrader), targeting various immunological diseases[27] - Kymera expects to report Phase 2b AD study data by mid-2027 and Phase 2b asthma study data in late-2027 for KT-621[27, 92] - A Phase 1 healthy volunteer trial for KT-579 is expected to initiate in Q1 2026, with data reported in 2H 2026[27, 92] - Sanofi plans to advance KT-485 into a Phase 1 clinical trial in 2026[14, 91] KT-621 Clinical Data and Market Opportunity - KT-621 has shown deep STAT6 degradation (>95%) in healthy volunteers and AD patients[44] - In the BroADen Phase 1b AD trial, KT-621 achieved significant reductions in EASI score (-63%), Total SCORAD (-48%), Peak Pruritus NRS (-40%), and SCORAD-Itch (-44%)[53, 54, 57] - KT-621 also demonstrated improvements in patient-reported outcomes, with 61% DLQI responders and 75% POEM responders[60] - KT-621 achieved a 56% median FeNO reduction in AD patients with comorbid asthma[71] - The potential patient impact for STAT6 inhibition in Type 2 inflammation is estimated to be >140 million, representing a >$20 billion market[35] Financial Position - Kymera is capitalized with $1.6 billion in cash, providing a runway into 2029[14]

Financial Position - Kymera Therapeutics has $1.6 billion in cash, providing a runway into 2029[1] Clinical Trials - The KT-621 BROADEN2 Phase 2b trial in atopic dermatitis (AD) is ongoing, with data expected by mid-2027, and the trial includes approximately 200 patients[6] - The KT-621 BREADTH Phase 2b trial in asthma has been initiated, with data expected in late-2027, involving approximately 264 adult patients[6] - KT-621 received FDA Fast Track designation for the treatment of moderate to severe AD in December 2025[6] - In December 2025, KT-621 demonstrated significant reductions in Type 2 inflammatory biomarkers and improvements in clinical endpoints in a Phase 1b trial[6] - The primary endpoint for the BROADEN2 trial is the percent change from baseline in Eczema Area and Severity Index (EASI) score at week 16[6] - The primary endpoint for the BREADTH trial is the percent change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1)[6] Development Pipeline - The company plans to advance at least one new development candidate towards IND for a first-in-class oral immunology program in 2026[10] - KT-579, an investigational oral degrader, is expected to initiate its first-in-human Phase 1 trial in Q1 2026, with data anticipated in the second half of 2026[9] Strategic Vision - Kymera aims to reshape the treatment of common immuno-inflammatory diseases with its innovative oral therapies[2]

Core Insights - Kymera Therapeutics is advancing a new class of oral small molecule degrader medicines for immunological diseases, with significant clinical milestones expected in 2026 and beyond [1][2][14] Pipeline Developments - KT-621 is in Phase 2b trials for atopic dermatitis (AD) and asthma, with data expected by mid-2027 and late-2027 respectively [1][10] - KT-579 is set to initiate a Phase 1 clinical trial in healthy volunteers in Q1 2026, with data anticipated in the second half of 2026 [1][8] - The company aims to advance at least one new development candidate towards IND for a first-in-class oral immunology program in 2026 [1][12] Financial Position - Kymera is well-capitalized with $1.6 billion in cash, providing a runway into 2029 [1][2] Clinical Trial Updates - KT-621 has shown promising results in a Phase 1b trial for moderate to severe AD, demonstrating deep STAT6 degradation and significant improvements in clinical endpoints [4] - The BROADEN2 Phase 2b trial for KT-621 includes approximately 200 patients and aims to evaluate efficacy, safety, and tolerability over 16 weeks [10] - The BREADTH Phase 2b trial for KT-621 in eosinophilic asthma will involve around 264 adult patients over 12 weeks [10] Strategic Vision - The company is focused on transforming treatment paradigms for over 140 million patients suffering from Type 2 diseases, aiming to deliver oral medicines that can change the standard of care [2][3]

Core Viewpoint - Kymera Therapeutics, Inc. (KYMR) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which are a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements, making it a valuable tool for investors [2][4]. - The recent upgrade reflects an improvement in Kymera Therapeutics' underlying business, suggesting that investor sentiment may lead to increased stock prices [5]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Kymera Therapeutics is expected to report earnings of -$3.49 per share, unchanged from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Kymera has increased by 7.6%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Kymera Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].